Your clinical trial runs through a CRO and a chain of external vendors.
We manage and oversee every one of them, on your behalf.

Almost every biotech founder says the same thing: "This trial is such a mess." And it does not happen at one company, it happens at almost all of them.

From the outside, a clinical trial looks like an orderly process: there is a CRO, there are vendors, there are sites, there is an internal team. On paper, everything is divided up. In practice, it all feels like one big chaos.

Why? Because responsibility for the trial did not really move to the CRO. The sponsor is still accountable for everything: the decisions, the logistics, the day to day activities that stay inside the company, the coordination, the vendors, and everything that happens between all of them.

At the very same time, the CRO works inside its own system, the vendors work through different interfaces, the sites are trying to get answers on time, and the company itself is trying to understand what it is even supposed to do day to day.

When there is no single layer connecting all of this, that is exactly what you feel: mess, chaos, loss of control. Not because people are working badly, but because there is no real connection between the parts.

One more critical point: many of the activities that stay with the sponsor are not fully clear from day one. So they get delayed, missed, or simply fall between the chairs under all the load.

At Myrtle Clinical, this is exactly where we step in. Not to replace the CRO, and not to replace the sponsor, but to place one layer above everyone that connects the entire trial into a single system.

In practice: you see the whole trial in one place. We connect the sponsor, the CRO, the vendors and the sites. We make sure the work that stays inside the company actually happens. We catch gaps before they become delays. And we turn the feeling of chaos into one coordinated system.

Because in the end it is simple: a clinical trial should not feel like ongoing chaos. It should feel like one system that works.

Do not cut corners on an independent oversight and management layer for the trial you are leading.

"We only pay the CRO when they hit the milestone." I often hear this framed as oversight. I see it differently.

Milestone based payment measures whether a task was completed. It does not tell you whether the trial is being managed well. It does not tell you why the same issue keeps reappearing every week, whether timelines are slipping because of weak execution or unrealistic resourcing, whether a site needs another study coordinator, whether the CRA is overloaded, or whether the protocol was ever made truly usable for the people expected to follow it.

And when payment becomes the main control mechanism, people focus on protecting the metric rather than openly surfacing what is actually going wrong.

Real oversight is not about making vendors work under fear. It is about understanding what stands between the trial and success, and fixing it. Sometimes that means escalation. Sometimes stronger accountability. Sometimes more support, clearer processes, better communication, or additional resources where they are genuinely needed.

The goal is not to catch the CRO. The goal is to make the trial better. Better managed, better supported, better controlled, and far more likely to deliver reliable results.

Hiring a strong CRO is the start. Getting that CRO's best execution for your trial is what independent oversight secures. This is not about doubt. It is simply how outsourced delivery works at its best.

When a biotech, pharma or medical device company outsources a study, it transfers a large part of the budget and the execution responsibility to the CRO. From that point, the company depends on the CRO to drive sites, vendors, timelines and operational delivery.

So an important question arises: where does your study sit inside the CRO's priorities? CROs juggle many sponsors, studies, resource constraints and competing deadlines. Oversight makes sure your study gets the urgency, continuity and attention it deserves, and that everything stays visible, not just what surfaces on a weekly update call.

You usually read it between the lines: the pace of follow up, how quickly issues are resolved, CRA or project manager continuity, SDV recovery, whether vendor issues are driven to closure, and how strong site engagement stays.

Oversight turns payment into performance. The company understands exactly where its study stands inside the CRO's priorities, what to measure, and how to read between the reports.

That is exactly the kind of independent oversight that makes the CRO, the vendors and the sites work better for your trial, with stronger commitment, sharper focus, and clearer accountability.

The clinical trials industry is becoming more efficient, but also more fragmented.

The FDA aligned ICH M15 guideline on Model Informed Drug Development is accelerating faster, data driven development in pharma and medical device companies. More efficiency means more programs, more trials, and more outsourcing to CROs and vendors. Not less complexity, more of it.

The direction is clear: more parallel development, more global execution networks, and more distributed responsibility. Accountability, however, stays with the company developing the product.

Execution is now split across multiple CROs, vendors and service providers. Each optimizes its own part. No one owns the full system.

This is why structured CRO and vendor oversight is the missing piece in most clinical programs. Not reporting. Not dashboards. Real operational control: quality, data integrity, protocol adherence, and alignment across every vendor.

Without it, there is no control. Only coordination. And coordination breaks at scale.